We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TU:NYSETelus Corporation Analysis

Data as of 2026-08-02 - not real-time

$9.56

Latest Price

8/10Risk

Risk Level: High

Executive Summary

TELUS shares are trading at $9.56, well below the 20‑day (≈10.40), 50‑day (≈11.25) and 200‑day (≈12.87) moving averages, signaling a bearish technical backdrop. The RSI of 32 points to oversold conditions, while the MACD histogram has turned positive, hinting at a potential short‑term bounce as volume continues to rise. The recent appointment of Victor Dodig as President and CEO adds a leadership catalyst that could support a strategic reset.
Fundamentally, the company posted a modest revenue decline of 0.6% and a thin profit margin of 4.5%, with trailing EPS still negative despite a forward EPS estimate of $0.69. The dividend yield appears attractive at 12.3%, but a payout ratio of 278% flags unsustainability. A massive debt load (≈$31 bn) drives a debt‑to‑equity ratio above 190, and the DCF‑derived fair value of roughly $1.02 is dramatically lower than the current market price, indicating significant overvaluation. Volatility is elevated at over 43% annualized, though beta is near zero, suggesting limited market‑wide sensitivity but high company‑specific risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support with bearish SMA alignment
  • Oversold RSI and emerging bullish MACD signal
  • Increasing volume suggesting possible short‑term rebound

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Leadership transition to Victor Dodig
  • Persistently low profitability and high leverage
  • Dividend yield attractiveness offset by unsustainable payout

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF fair value far below market price
  • Elevated debt‑to‑equity ratio limiting financial flexibility
  • Weak earnings outlook and negative trailing EPS

Key Metrics & Analysis

Financial Health

Revenue Growth-0.60%
Profit Margin4.57%
P/E Ratio13.9
ROE3.74%
ROA3.44%
Debt/Equity190.14
P/B Ratio1.4
Op. Cash Flow$4.8B
Free Cash Flow$2.5B
Industry P/E15.7

Technical Analysis

TrendBearish
RSI32.4
Support$9.22
Resistance$11.14
MA 20$10.40
MA 50$11.25
MA 200$12.87
MACDBullish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Fair Value$1.02
Target Price$16.67
Upside/Downside74.34%
GradeOvervalued
TypeValue
Dividend Yield12.33%

Risk Assessment

Beta0.01
Volatility43.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.